KR102326068B1 - 레트로바이러스에 의해 야기되는 질병 치료에 유용한 이고리 화합물 - Google Patents
레트로바이러스에 의해 야기되는 질병 치료에 유용한 이고리 화합물 Download PDFInfo
- Publication number
- KR102326068B1 KR102326068B1 KR1020167003323A KR20167003323A KR102326068B1 KR 102326068 B1 KR102326068 B1 KR 102326068B1 KR 1020167003323 A KR1020167003323 A KR 1020167003323A KR 20167003323 A KR20167003323 A KR 20167003323A KR 102326068 B1 KR102326068 B1 KR 102326068B1
- Authority
- KR
- South Korea
- Prior art keywords
- virus
- group
- diseases
- nmr
- mhz
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 0 CCCCC[C@@](C)CN(C)C(NC1=CC*(COC)CC[C@]1CC)=CC=C Chemical compound CCCCC[C@@](C)CN(C)C(NC1=CC*(COC)CC[C@]1CC)=CC=C 0.000 description 2
- IYLUIBBHBDWNTE-UHFFFAOYSA-N Brc(cccc1cc2)c1nc2Nc1nccnc1 Chemical compound Brc(cccc1cc2)c1nc2Nc1nccnc1 IYLUIBBHBDWNTE-UHFFFAOYSA-N 0.000 description 1
- LISWVEFPCRYFAV-YXKQOGFESA-N CCC(NCCC/C=C1\[C@H](C(C)C)NCCCC1)N(C)CC(C)C Chemical compound CCC(NCCC/C=C1\[C@H](C(C)C)NCCCC1)N(C)CC(C)C LISWVEFPCRYFAV-YXKQOGFESA-N 0.000 description 1
- MIAOLNOVJZQJGS-SYRBMCIYSA-N CCCCC[C@H](CCC)C/N=C/N[C@@H](CC)N/C=C\C Chemical compound CCCCC[C@H](CCC)C/N=C/N[C@@H](CC)N/C=C\C MIAOLNOVJZQJGS-SYRBMCIYSA-N 0.000 description 1
- HXSRVNNGYLTTNM-WOJBJXKFSA-N CC[C@@H](N[C@H](C1)C(C)=CCC=C1OC(F)F)NC1=C(C)CCC=CCC1 Chemical compound CC[C@@H](N[C@H](C1)C(C)=CCC=C1OC(F)F)NC1=C(C)CCC=CCC1 HXSRVNNGYLTTNM-WOJBJXKFSA-N 0.000 description 1
- VXBYNYBZMRMLGW-UHFFFAOYSA-N CCc1c(Nc(ccc2ccc3)nc2c3Cl)nc(C)cc1 Chemical compound CCc1c(Nc(ccc2ccc3)nc2c3Cl)nc(C)cc1 VXBYNYBZMRMLGW-UHFFFAOYSA-N 0.000 description 1
- LSRLBKXWOIDDGO-UHFFFAOYSA-N COc1c(Nc2cnc(cccc3)c3c2)nccc1 Chemical compound COc1c(Nc2cnc(cccc3)c3c2)nccc1 LSRLBKXWOIDDGO-UHFFFAOYSA-N 0.000 description 1
- PAZITGANORKJQX-UHFFFAOYSA-N Cc(cccc1cc2)c1nc2Nc(cc1)ccc1OC(F)(F)F Chemical compound Cc(cccc1cc2)c1nc2Nc(cc1)ccc1OC(F)(F)F PAZITGANORKJQX-UHFFFAOYSA-N 0.000 description 1
- VXECRKRPJRAULJ-UHFFFAOYSA-N Cc(ccnc1Nc2cnc(cccc3)c3n2)c1[N+]([O-])=O Chemical compound Cc(ccnc1Nc2cnc(cccc3)c3n2)c1[N+]([O-])=O VXECRKRPJRAULJ-UHFFFAOYSA-N 0.000 description 1
- RUIHEVIZDKFBBX-UHFFFAOYSA-N Cc1c(Nc2ncc(C(F)(F)F)cc2)nc(cccc2)c2c1 Chemical compound Cc1c(Nc2ncc(C(F)(F)F)cc2)nc(cccc2)c2c1 RUIHEVIZDKFBBX-UHFFFAOYSA-N 0.000 description 1
- GBGBPIZOYJCRCB-UHFFFAOYSA-N Cc1c(cncc2)c2c(C)c(Nc2ncc(C(F)(F)F)cc2)c1 Chemical compound Cc1c(cncc2)c2c(C)c(Nc2ncc(C(F)(F)F)cc2)c1 GBGBPIZOYJCRCB-UHFFFAOYSA-N 0.000 description 1
- FPOCSJDULFADOD-UHFFFAOYSA-N Cc1cc(C)nc(Nc(ccc2ccc3)nc2c3Cl)c1 Chemical compound Cc1cc(C)nc(Nc(ccc2ccc3)nc2c3Cl)c1 FPOCSJDULFADOD-UHFFFAOYSA-N 0.000 description 1
- VGWOMTPTPCNRSD-UHFFFAOYSA-N Cc1ccnc(Nc(ccc2ccc3)nc2c3Cl)c1N Chemical compound Cc1ccnc(Nc(ccc2ccc3)nc2c3Cl)c1N VGWOMTPTPCNRSD-UHFFFAOYSA-N 0.000 description 1
- SVMQCHZHOIOPBT-UHFFFAOYSA-N Clc1ccnc(Nc2ccc(cccc3Cl)c3n2)c1 Chemical compound Clc1ccnc(Nc2ccc(cccc3Cl)c3n2)c1 SVMQCHZHOIOPBT-UHFFFAOYSA-N 0.000 description 1
- LHEPULDUSUAMAY-UHFFFAOYSA-N N#Cc1ccc(Nc2ccc(cccc3)c3n2)nc1 Chemical compound N#Cc1ccc(Nc2ccc(cccc3)c3n2)nc1 LHEPULDUSUAMAY-UHFFFAOYSA-N 0.000 description 1
- GKQWGUCKPKFKBV-UHFFFAOYSA-N Nc1cccnc1Nc1cc2ccccc2nc1 Chemical compound Nc1cccnc1Nc1cc2ccccc2nc1 GKQWGUCKPKFKBV-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/472—Non-condensed isoquinolines, e.g. papaverine
- A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
- A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/498—Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Virology (AREA)
- Communicable Diseases (AREA)
- Immunology (AREA)
- Oncology (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Dermatology (AREA)
- Hematology (AREA)
- Molecular Biology (AREA)
- Transplantation (AREA)
- Pulmonology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Diabetes (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361843155P | 2013-07-05 | 2013-07-05 | |
| US61/843,155 | 2013-07-05 | ||
| PCT/IB2014/062849 WO2015001518A1 (en) | 2013-07-05 | 2014-07-04 | Bicyclic compounds useful for treating diseases caused by retroviruses |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| KR20160032724A KR20160032724A (ko) | 2016-03-24 |
| KR102326068B1 true KR102326068B1 (ko) | 2021-11-11 |
Family
ID=51453778
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020167003323A Active KR102326068B1 (ko) | 2013-07-05 | 2014-07-04 | 레트로바이러스에 의해 야기되는 질병 치료에 유용한 이고리 화합물 |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US9827237B2 (enExample) |
| EP (1) | EP3016656B1 (enExample) |
| JP (2) | JP6895251B2 (enExample) |
| KR (1) | KR102326068B1 (enExample) |
| CN (1) | CN105530938B (enExample) |
| AU (1) | AU2014285733B2 (enExample) |
| BR (1) | BR112016000127B1 (enExample) |
| CA (1) | CA2916623C (enExample) |
| ES (1) | ES2898385T3 (enExample) |
| HR (1) | HRP20211839T1 (enExample) |
| MX (1) | MX382692B (enExample) |
| PL (1) | PL3016656T3 (enExample) |
| PT (1) | PT3016656T (enExample) |
| RU (1) | RU2681943C9 (enExample) |
| WO (1) | WO2015001518A1 (enExample) |
| ZA (1) | ZA201600317B (enExample) |
Families Citing this family (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2974729A1 (en) | 2014-07-17 | 2016-01-20 | Abivax | Quinoline derivatives for use in the treatment of inflammatory diseases |
| EP3059591A1 (en) * | 2015-02-23 | 2016-08-24 | Abivax | Methods for screening compounds for treating or preventing a viral infection or a virus-related condition |
| EP3058940A1 (en) * | 2015-02-23 | 2016-08-24 | Abivax | Quinoline derivatives for use in the treatment or prevention of viral infection |
| EP3059236A1 (en) * | 2015-02-23 | 2016-08-24 | Abivax | A new quinoline derivative for use in the treatment and prevention of viral infections |
| KR20170109160A (ko) | 2016-03-18 | 2017-09-28 | 현대자동차주식회사 | 엔진마운트의 체결구조 |
| US11168068B2 (en) | 2016-07-18 | 2021-11-09 | Janssen Pharmaceutica Nv | Tau PET imaging ligands |
| EP3594205A1 (en) | 2018-07-09 | 2020-01-15 | Abivax | Phenyl-n-aryl derivatives for treating a rna virus infection |
| EP3594206A1 (en) | 2018-07-09 | 2020-01-15 | Abivax | Phenyl-n-quinoline derivatives for treating a rna virus infection |
| EP3669873A1 (en) | 2018-12-20 | 2020-06-24 | Abivax | Quinoline derivatives for use ine the traeatment of inflammation diseases |
| EP3848356A1 (en) * | 2020-01-07 | 2021-07-14 | Abivax | Aryl-n-aryl derivatives for treating a rna virus infection |
| US11753413B2 (en) | 2020-06-19 | 2023-09-12 | Incyte Corporation | Substituted pyrrolo[2,1-f][1,2,4]triazine compounds as JAK2 V617F inhibitors |
| US11691971B2 (en) | 2020-06-19 | 2023-07-04 | Incyte Corporation | Naphthyridinone compounds as JAK2 V617F inhibitors |
| ES3035284T3 (en) | 2020-07-02 | 2025-09-01 | Incyte Corp | Tricyclic urea compounds as jak2 v617f inhibitors |
| US11767323B2 (en) | 2020-07-02 | 2023-09-26 | Incyte Corporation | Tricyclic pyridone compounds as JAK2 V617F inhibitors |
| WO2022046989A1 (en) | 2020-08-27 | 2022-03-03 | Incyte Corporation | Tricyclic urea compounds as jak2 v617f inhibitors |
| TW202237119A (zh) | 2020-12-10 | 2022-10-01 | 美商住友製藥腫瘤公司 | Ａｌｋ﹘５抑制劑和彼之用途 |
| US11919908B2 (en) | 2020-12-21 | 2024-03-05 | Incyte Corporation | Substituted pyrrolo[2,3-d]pyrimidine compounds as JAK2 V617F inhibitors |
| CA3211748A1 (en) | 2021-02-25 | 2022-09-01 | Incyte Corporation | Spirocyclic lactams as jak2 v617f inhibitors |
| MX2023013972A (es) | 2021-05-27 | 2023-12-11 | Jiangsu Hengrui Pharmaceuticals Co Ltd | Compuesto de quinolinamina, metodo de preparacion y aplicacion del mismo en productos farmaceuticos. |
| PE20251706A1 (es) | 2022-03-17 | 2025-07-02 | Incyte Corp | Compuestos de urea triciclica como inhibidores de v617f de jak2 |
| CN116120282B (zh) * | 2022-08-04 | 2024-02-20 | 苏州系统医学研究所 | 具有ev71和/或cva16病毒抑制活性的化合物及其应用 |
| CN120152971A (zh) | 2022-11-25 | 2025-06-13 | 江苏恒瑞医药股份有限公司 | 一种喹啉胺类化合物晶型及其制备方法 |
| CN118373771A (zh) | 2023-01-20 | 2024-07-23 | 江苏柯菲平医药股份有限公司 | 一种喹啉衍生化合物或其可药用的盐及其制备方法和应用 |
| WO2025045123A1 (zh) * | 2023-08-30 | 2025-03-06 | 江苏正大丰海制药有限公司 | 用于调节微小rna-124活性的化合物 |
Family Cites Families (36)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB585362A (en) | 1944-08-31 | 1947-02-05 | Francis Henry Swinden Curd | New heterocyclic compounds |
| BE486034A (enExample) | 1947-11-28 | |||
| DE958647C (de) | 1952-12-28 | 1957-02-21 | Hoechst Ag | Verfahren zur Herstellung von 7-Amino-2-oxy-4-methyl-chinolinen |
| FR2387229A1 (fr) | 1977-04-13 | 1978-11-10 | Anvar | Dipyrido (4,3-b) (3,4-f) indoles, procede d'obtention, application therapeutique et compositions pharmaceutiques les contenant |
| FR2436786A1 (fr) | 1978-09-21 | 1980-04-18 | Anvar | Nouveaux derives des pyrido (4,3-b) carbazoles (ellipticines), substitues en position 1 par une chaine polyaminee, leur obtention et leur application a titre de medicaments |
| FR2627493B1 (fr) | 1988-02-23 | 1991-10-31 | Sanofi Sa | Procede de preparation de derives d'isoquinoleine |
| FR2645861A1 (fr) | 1989-04-17 | 1990-10-19 | Inst Nat Sante Rech Med | Utilisation de dipyrido (4,3-b) (3,4-f) indoles pour la preparation de medicaments utiles pour le traitement du sida |
| US6177401B1 (en) | 1992-11-13 | 2001-01-23 | Max-Planck-Gesellschaft Zur Forderung Der Wissenschaften | Use of organic compounds for the inhibition of Flk-1 mediated vasculogenesis and angiogenesis |
| EP1165064B1 (en) | 1999-04-05 | 2004-02-25 | City of Hope | Novel inhibitors of formation of advanced glycation endproducts (age's) |
| UA75055C2 (uk) | 1999-11-30 | 2006-03-15 | Пфайзер Продактс Інк. | Похідні бензоімідазолу, що використовуються як антипроліферативний засіб, фармацевтична композиція на їх основі |
| DE10013318A1 (de) | 2000-03-17 | 2001-09-20 | Merck Patent Gmbh | Formulierung enthaltend Chinoxalinderivate |
| AU2002303078B2 (en) | 2001-01-22 | 2007-08-30 | Memory Pharmaceuticals Corporation | Aniline derivatives useful as phosphodiesterase 4 inhibitors |
| MXPA04011472A (es) | 2002-05-22 | 2005-02-14 | Amgen Inc | Derivados de amino-piridina, piridina y piridazina para usarse como ligandos del receptor vaniloide para el tratamiento del dolor. |
| AU2002950217A0 (en) | 2002-07-16 | 2002-09-12 | Prana Biotechnology Limited | 8- Hydroxy Quinoline Derivatives |
| CN1688545A (zh) | 2002-07-19 | 2005-10-26 | 记忆药物公司 | 磷酸二酯酶4抑制剂,包括n－取代的苯胺及二苯胺类似物 |
| FR2849474B3 (fr) | 2002-12-27 | 2004-12-03 | Olivier Jean Noel Juin | Installation de transformation de l'energie cinetique d'un fluide en energie electrique |
| WO2004078731A1 (en) | 2003-03-06 | 2004-09-16 | 'chemical Diversity Research Institute', Ltd. | Quinoline-carboxylic acids and the derivatives thereof, a focused library |
| FR2859475A1 (fr) | 2003-09-04 | 2005-03-11 | Centre Nat Rech Scient | Utilisation de composes derives d'ellipticine et d'aza-ellipticine pour la preparation d'un medicament utile pour le traitement de maladies genetiques resultant de l'alteration des processus d'epissage |
| FR2859474B1 (fr) | 2003-09-04 | 2006-01-13 | Centre Nat Rech Scient | Utilisation de composes derives d'indole pour la preparation d'un medicament utile pour le traitement de maladies genetiques resultant de l'alteration des processus d'epissage |
| CN1905873A (zh) | 2003-11-19 | 2007-01-31 | 阵列生物制药公司 | Mek的杂环抑制剂及其使用方法 |
| EP1853265B1 (en) | 2005-01-28 | 2016-01-27 | The Government of the United States of America as represented by the Secretary of the Department of Health and Human Services | Farnesyltransferase inhibitors for use in the treatment of laminopathies, cellular aging and atherosclerosis |
| FR2903312B1 (fr) | 2006-07-05 | 2008-09-26 | Univ Aix Marseille Ii | Utilisation d'inhibiteurs d'hmg-coa reductase et de farnesyl-pyrophosphate synthase dans la preparation d'un medicament |
| US8030487B2 (en) | 2006-07-07 | 2011-10-04 | Targegen, Inc. | 2-amino—5-substituted pyrimidine inhibitors |
| AU2008206045A1 (en) | 2007-01-19 | 2008-07-24 | Ardea Biosciences, Inc. | Inhibitors of MEK |
| FR2912745A1 (fr) | 2007-02-19 | 2008-08-22 | Centre Nat Rech Scient | Nouveaux composes derives d'indole et compositions pharmaceutiques les contenant |
| CA2681481A1 (en) | 2007-03-16 | 2008-09-25 | Mount Sinai School Of Medicine | Induction and/or maintenance of tumor dormancy by disruption of urokinase plasminogen activator receptor-integrin interaction |
| WO2008143440A1 (en) | 2007-05-17 | 2008-11-27 | Lg Chem, Ltd. | New anthracene derivatives and organic electronic device using the same |
| JP2010536789A (ja) | 2007-08-15 | 2010-12-02 | メモリー・ファーマシューティカルズ・コーポレイション | ５−ｈｔ６受容体親和性を有する３’置換化合物 |
| WO2009029617A1 (en) | 2007-08-27 | 2009-03-05 | Kalypsys, Inc. | Diarylamine-substituted quinolones useful as inducible nitric oxide synthase inhibitors |
| FR2926297B1 (fr) | 2008-01-10 | 2013-03-08 | Centre Nat Rech Scient | Molecules chimiques inhibitrices du mecanisme d'epissage pour traiter des maladies resultant d'anomalies d'epissage. |
| EP2266972A1 (en) | 2009-06-12 | 2010-12-29 | Splicos | New chemical molecules that inhibit the splicing mechanism for treating diseases resulting from splicing anomalies |
| EP2440546B1 (en) | 2009-06-12 | 2022-12-28 | Abivax | Compounds useful for treating premature aging and in particular progeria |
| WO2010151755A2 (en) | 2009-06-25 | 2010-12-29 | The Brigham And Women's Hospital, Inc. | TREATMENT OF INFLAMMATORY DISEASES USING miR-124 |
| EP2465502A1 (en) * | 2010-12-15 | 2012-06-20 | Société Splicos | Compounds useful for treating AIDS |
| JP2016504268A (ja) | 2012-10-04 | 2016-02-12 | オヤジェン インコーポレイテッドＯｙａＧｅｎ， Ｉｎｃ． | Ｖｉｆの自己会合を撹乱する抗ｈｉｖ剤としての小分子及びその使用方法 |
| EP2757161A1 (en) * | 2013-01-17 | 2014-07-23 | Splicos | miRNA-124 as a biomarker of viral infection |
-
2014
- 2014-07-04 ES ES14758168T patent/ES2898385T3/es active Active
- 2014-07-04 PL PL14758168T patent/PL3016656T3/pl unknown
- 2014-07-04 AU AU2014285733A patent/AU2014285733B2/en active Active
- 2014-07-04 WO PCT/IB2014/062849 patent/WO2015001518A1/en not_active Ceased
- 2014-07-04 US US14/902,935 patent/US9827237B2/en active Active
- 2014-07-04 PT PT147581680T patent/PT3016656T/pt unknown
- 2014-07-04 BR BR112016000127-3A patent/BR112016000127B1/pt active IP Right Grant
- 2014-07-04 EP EP14758168.0A patent/EP3016656B1/en active Active
- 2014-07-04 HR HRP20211839TT patent/HRP20211839T1/hr unknown
- 2014-07-04 JP JP2016522952A patent/JP6895251B2/ja active Active
- 2014-07-04 MX MX2015017599A patent/MX382692B/es unknown
- 2014-07-04 RU RU2016103217A patent/RU2681943C9/ru active
- 2014-07-04 CA CA2916623A patent/CA2916623C/en active Active
- 2014-07-04 KR KR1020167003323A patent/KR102326068B1/ko active Active
- 2014-07-04 CN CN201480038497.4A patent/CN105530938B/zh active Active
-
2016
- 2016-01-14 ZA ZA2016/00317A patent/ZA201600317B/en unknown
-
2019
- 2019-04-26 JP JP2019086240A patent/JP2019142946A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| ES2898385T3 (es) | 2022-03-07 |
| ZA201600317B (en) | 2018-07-25 |
| RU2681943C2 (ru) | 2019-03-14 |
| US20160151348A1 (en) | 2016-06-02 |
| MX382692B (es) | 2025-03-13 |
| PT3016656T (pt) | 2021-11-26 |
| HRP20211839T1 (hr) | 2022-03-04 |
| KR20160032724A (ko) | 2016-03-24 |
| CN105530938A (zh) | 2016-04-27 |
| BR112016000127B1 (pt) | 2022-02-15 |
| AU2014285733A1 (en) | 2016-01-21 |
| EP3016656A1 (en) | 2016-05-11 |
| RU2681943C9 (ru) | 2019-05-16 |
| CN105530938B (zh) | 2019-10-22 |
| HK1217447A1 (zh) | 2017-01-13 |
| US9827237B2 (en) | 2017-11-28 |
| JP2019142946A (ja) | 2019-08-29 |
| JP6895251B2 (ja) | 2021-06-30 |
| JP2016523893A (ja) | 2016-08-12 |
| CA2916623A1 (en) | 2015-01-08 |
| PL3016656T3 (pl) | 2022-02-21 |
| AU2014285733B2 (en) | 2019-05-16 |
| WO2015001518A1 (en) | 2015-01-08 |
| MX2015017599A (es) | 2016-04-07 |
| RU2016103217A (ru) | 2017-08-10 |
| CA2916623C (en) | 2021-09-14 |
| EP3016656B1 (en) | 2021-09-08 |
| BR112016000127A8 (pt) | 2018-01-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR102326068B1 (ko) | 레트로바이러스에 의해 야기되는 질병 치료에 유용한 이고리 화합물 | |
| EP2440547B1 (en) | New chemical molecules that inhibit the splicing mechanism for the treatment of diseases resulting from splicing defects | |
| JP6694476B2 (ja) | Ａｉｄｓを治療する為に有用な化合物 | |
| RU2575845C2 (ru) | Соединения, пригодные для лечения спида | |
| HK40086860A (en) | Preparation of compounds useful for treating aids | |
| HK1217447B (zh) | 用於治疗由逆转录病毒引起的疾病的化合物 | |
| HK1173726B (en) | Compounds useful for treating aids |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PA0105 | International application |
St.27 status event code: A-0-1-A10-A15-nap-PA0105 |
|
| P11-X000 | Amendment of application requested |
St.27 status event code: A-2-2-P10-P11-nap-X000 |
|
| P13-X000 | Application amended |
St.27 status event code: A-2-2-P10-P13-nap-X000 |
|
| R15-X000 | Change to inventor requested |
St.27 status event code: A-3-3-R10-R15-oth-X000 |
|
| R16-X000 | Change to inventor recorded |
St.27 status event code: A-3-3-R10-R16-oth-X000 |
|
| PG1501 | Laying open of application |
St.27 status event code: A-1-1-Q10-Q12-nap-PG1501 |
|
| A201 | Request for examination | ||
| PA0201 | Request for examination |
St.27 status event code: A-1-2-D10-D11-exm-PA0201 |
|
| E902 | Notification of reason for refusal | ||
| PE0902 | Notice of grounds for rejection |
St.27 status event code: A-1-2-D10-D21-exm-PE0902 |
|
| AMND | Amendment | ||
| E13-X000 | Pre-grant limitation requested |
St.27 status event code: A-2-3-E10-E13-lim-X000 |
|
| P11-X000 | Amendment of application requested |
St.27 status event code: A-2-2-P10-P11-nap-X000 |
|
| P13-X000 | Application amended |
St.27 status event code: A-2-2-P10-P13-nap-X000 |
|
| E902 | Notification of reason for refusal | ||
| PE0902 | Notice of grounds for rejection |
St.27 status event code: A-1-2-D10-D21-exm-PE0902 |
|
| AMND | Amendment | ||
| E13-X000 | Pre-grant limitation requested |
St.27 status event code: A-2-3-E10-E13-lim-X000 |
|
| P11-X000 | Amendment of application requested |
St.27 status event code: A-2-2-P10-P11-nap-X000 |
|
| P13-X000 | Application amended |
St.27 status event code: A-2-2-P10-P13-nap-X000 |
|
| E601 | Decision to refuse application | ||
| PE0601 | Decision on rejection of patent |
St.27 status event code: N-2-6-B10-B15-exm-PE0601 |
|
| AMND | Amendment | ||
| E13-X000 | Pre-grant limitation requested |
St.27 status event code: A-2-3-E10-E13-lim-X000 |
|
| P11-X000 | Amendment of application requested |
St.27 status event code: A-2-2-P10-P11-nap-X000 |
|
| P13-X000 | Application amended |
St.27 status event code: A-2-2-P10-P13-nap-X000 |
|
| PX0901 | Re-examination |
St.27 status event code: A-2-3-E10-E12-rex-PX0901 |
|
| PX0701 | Decision of registration after re-examination |
St.27 status event code: A-3-4-F10-F13-rex-PX0701 |
|
| X701 | Decision to grant (after re-examination) | ||
| GRNT | Written decision to grant | ||
| PR0701 | Registration of establishment |
St.27 status event code: A-2-4-F10-F11-exm-PR0701 |
|
| PR1002 | Payment of registration fee |
St.27 status event code: A-2-2-U10-U12-oth-PR1002 Fee payment year number: 1 |
|
| PG1601 | Publication of registration |
St.27 status event code: A-4-4-Q10-Q13-nap-PG1601 |
|
| R18-X000 | Changes to party contact information recorded |
St.27 status event code: A-5-5-R10-R18-oth-X000 |
|
| R18-X000 | Changes to party contact information recorded |
St.27 status event code: A-5-5-R10-R18-oth-X000 |
|
| PR1001 | Payment of annual fee |
St.27 status event code: A-4-4-U10-U11-oth-PR1001 Fee payment year number: 4 |
|
| PR1001 | Payment of annual fee |
St.27 status event code: A-4-4-U10-U11-oth-PR1001 Fee payment year number: 5 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-OTH-PR1001 (AS PROVIDED BY THE NATIONAL OFFICE) Year of fee payment: 5 |